David Gill

David Gill

Director/Board Member at EVOLUS, INC.

Net worth: 271 112 $ as of 31/05/2026

71 year
Health Technology
Technology Services
Health Services

Profile

David Neil Gill is currently Independent Director at Evolus, Inc. since 2018; Director at The Alfred E.
Mann Foundation For Scientific Research, Bioretec Ltd. starting 2026, Bridge to Life Ltd., Allucent LLC, and RapidPulse, Inc.; Independent Non-Executive Director at Telix Pharmaceuticals Ltd. starting 2026; and Chief Financial Officer at Perspectum Group Ltd. since 2021.
Former roles include Chairman at Melinta Therapeutics, Inc. from 2019 to 2020; Independent Director at STRATA Skin Sciences, Inc. from 2018 to 2020; Independent Director at Histogenics Corp.
from 2015 to 2019; Independent Director at Cempra, Inc. from 2012 to 2020; Independent Director at Strongbridge Biopharma Plc from 2019 to 2021; Independent Director at Y-mAbs Therapeutics, Inc. from 2017 to 2025; Director at LeMaitre Vascular, Inc. from 2006 to 2008; Director at IsoTis OrthoBiologics, Inc. from 2006 to 2009; Chief Operating Officer at Novoste Corp.
from 1996 to 2000; President & Chief Operating Officer at Interland, Inc. from 2000 to 2001; Chief Financial Officer & Senior Vice President at CTI Molecular Imaging, Inc. from 2002 to 2005; President, Chief Operating & Financial Officer at EndoChoice, Inc. in 2016; Chief Financial Officer at TransEnterix, Inc. from 2009 to 2011; Chief Financial Officer at Syneos Health NC LLC from 2011 to 2013; Chief Financial Officer & Treasurer at NxStage Medical, Inc. from 2005 to 2006; Chief Financial Officer at INC Research Holdings, Inc. from 2011 to 2013; Chief Financial Officer at Perspectum Ltd. in 2021; Director at Calypso Medical Technologies, Inc. from 2000 to 2012; and Director at several other companies including IdleAire Technologies Corp., Cempra Pharmaceuticals, Inc., Novum Medical, Inc., EOS Imaging SA, and Azanta A. Education includes undergraduate studies at Wake Forest University and an MBA from Emory University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
17/04/2026 41,328 ( 0.06% ) 271 112 $ 31/05/2026

David Gill active positions

CompaniesPositionStart
BIORETEC OY Director/Board Member 08/05/2026
TELIX PHARMACEUTICALS LIMITED Director/Board Member 11/05/2026
EVOLUS, INC. Director/Board Member 12/02/2018
Director/Board Member -
Director/Board Member -
Director of Finance/CFO 09/07/2021
Director/Board Member -
Director/Board Member -

Former positions of David Gill

CompaniesPositionEnd
YMAS THER Director/Board Member 16/09/2025
░░░░░░░░░░ ░░░░ ░░░░░░░░ ░░ ░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░░
See the detail of David Gill's experience

Training of David Gill

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

60

1st degree connections

36

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies36

Health Technology

Technology Services

Health Technology

Health Technology

Health Technology

Producer Manufacturing

Health Services

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Commercial Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Miscellaneous

Dornier Medical Systems, Inc.

Health Technology

Health Technology

Health Technology

Commercial Services

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Technology Services

Health Technology

Technology Services

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!